Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961071 · ClinicalTrials.gov registry record · Phase 1
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
A Phase 1 study of Hypoparathyroidism and Hypoparathyroidism Postprocedural, sponsored by Peter Stock.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT06961071: Recruiting Phase 1 study of Hypoparathyroidism and Hypoparathyroidism Postprocedural, sponsored by Peter Stock.
NCT06961071 is a Phase 1 study of Hypoparathyroidism and Hypoparathyroidism Postprocedural that is actively recruiting participants, run by Peter Stock. The registered enrollment target is 3 participants, below the 199-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06961071, a Phase 1 study of Hypoparathyroidism and Hypoparathyroidism Postprocedural, is actively recruiting participants, sponsored by Peter Stock.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to see if transplanting parathyroid tissue into the forearm will help hypo-parathyroid patients achieve parathyroid hormone (PTH) levels that would help normalize their serum calcium and phosphorus levels. The parathyroid tissue used in this study will come from cadaveric tissues that were donated at the time of the death of the donor(s).
Primary Outcome
The primary efficacy endpoint is attainment of levels of intact PTH levels that are in the normal range and at least double the baseline intact PTH level at one year following the PTG transplant from a single donor.
Conditions Studied
Interventions
- BIOLOGICAL Parathyroid Allotransplant
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2028-01-15 |
| Phase | Phase 1 |
What NCT06961071 shows while recruiting
NCT06961071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 199-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Hypoparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which Parathyroid Allotransplant is the first listed.
NCT06961071 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06961071 about?
NCT06961071 is a clinical study titled "Parathyroid Allotransplant for Treatment of Hypoparathyroidism". This study is being done to see if transplanting parathyroid tissue into the forearm will help hypo-parathyroid patients achieve parathyroid hormone (PTH) levels that would help normalize their serum calcium and phosphorus levels. The parathyroid tissue used in this study will come from cadaveric ti...
What is the current status of trial NCT06961071?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2026-01-15. Estimated completion is 2028-01-15.
What conditions does trial NCT06961071 study?
This clinical trial studies the following conditions: Hypoparathyroidism, Hypoparathyroidism Postprocedural, Hypoparathyroidism Post-surgical.
What interventions are being tested in trial NCT06961071?
The interventions under investigation include: Parathyroid Allotransplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT06961071?
This trial is sponsored by Peter Stock, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961071 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06961071's enrollment target sits among peer trials
3 11th of 10 the lowest of 10 other Hypoparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
RECRUITING
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
A Registry for Participants With Chronic Hypoparathyroidism
ACTIVE NOT RECRUITING
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
ACTIVE NOT RECRUITING · Phase 2
-
Use of NPSP558 in the Treatment of Hypoparathyroidism
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI